Texas Rybelsus Lawsuit Attorney
Diabetes and Weight Loss Drug Injury
Our Texas Rybelsus lawsuit attorney team helps victims file Rybelsus lawsuits individually or join the Rybelsus class action lawsuit for serious health issues and medical conditions caused by the prescription drug. If you’re suffering the severe side effects of Rybelsus that weren’t included on the drug’s label, you may be eligible for financial compensation. Many Rybelsus lawsuits filed allege that Rybelsus causes gastroparesis (stomach paralysis), bowel obstruction or ileus, gastrointestinal problems, gallbladder disease, acute or necrotizing pancreatitis, kidney damage, thyroid tumors, sudden vision loss, or other side effects.
The Rybelsus lawyers at Reich & Binstock are experienced in holding pharmaceutical companies accountable. We’ve filed lawsuits for many diabetes drugs like Rybelsus and other semaglutide drugs, like Ozempic and Wegovy.
If you’ve sustained severe injuries while taking Rybelsus or other drugs like Ozempic and Wegovy, a skilled Texas Rybelsus attorney from our law firm can help you file a lawsuit against Novo Nordisk or Eli Lilly. For a free, no obligation case review, contact a Texas Rybelsus lawsuit attorney by calling 713-622-7271 or filling out our contact form.
Texas Rybelsus Lawyers Taking Rybelsus Claims Nationwide
Our Texas Rybelsus attorney group is filing lawsuits on behalf of Rybelsus patients across the country against popular weight loss drug and diabetes drug manufacturers, Novo Nordisk. The drug company is responsible for Rybelsus and other semaglutide medications, like Ozempic and Wegovy. All three drugs have been scrutinized.
Multiple lawsuits have alleged that the Rybelsus manufacturer, Novo Nordisk, failed to adequately warn consumers and doctors about potential health risks.
Many are now filing a Rybelsus lawsuit after experiencing serious side effects linked to this oral tablet, in the glucagon-like peptide 1 receptor agonist class. Used to treat type 2 diabetes, Rybelsus works by improving glycemic control and helping regulate insulin production.
More specifically, like other semaglutide drugs, Rybelsus works by mimicking the body’s natural GLP-1 hormone to stimulate insulin release, reduce glucagon secretion, and slow digestion. However, due to many cases of serious adverse reactions and Novo Nordisk’s failure to adequately warn, patients nationwide are filing Rybelsus lawsuits seeking justice and financial compensation for medical costs, missed work, and other expenses related to the health problems caused by semaglutide medications.
The Food and Drug Administration (FDA) approved the prescription drug in 2019 as the first glucagon-like peptide 1 receptor agonist oral medication. FDA approval was strictly as a diabetes drug. The oral medication treats type 2 diabetes by helping regulate blood sugar (improve glycemic control) in adults.
The high-risk medication is not approved as a weight loss drug but has been prescribed off-label by many doctors.
The warning label, like other semaglutide medications, included thyroid c-cell tumors based on rat-based scientific studies. It also warned doctors about pancreatitis, hypoglycemia, acute kidney injury, hypersensitivity reactions, and diabetic retinopathy issues.
In 2022, the Food and Drug Administration (FDA) issued a new warning, placing stronger emphasis on diabetic retinopathy as a severe health risk, following clinical trials that revealed serious eye conditions. Many patients and several law firms filing a Rybelsus lawsuit allege that the Rybelsus label understates how sudden vision loss can progress.
The Rybelsus label already lists nausea, vomiting, diarrhea, stomach pain, and decreased appetite as common side effects. However, the prescription drug’s label doesn’t list gastroparesis (stomach paralysis) or ileus (intestinal obstruction).
Then, in 2023, GLP-1 drugs were investigated for adverse event reports of consumers developing severe gastrointestinal issues, gastroparesis (stomach paralysis), and intestinal obstruction (ileus). None of these were listed as potential health risks on the Rybelsus label. Some wanted to take regulatory action to issue yet another new warning label, and this is why Rybelsus lawsuits and cases for popular weight loss drugs focus on these three health conditions.
Additionally, other adverse reactions and health risks linked to semaglutide drugs include gallbladder disease, gallstones, and inflammation. The risk factors have been noted across GLP-1 drugs like Rybelsus. The FDA is evaluating psychiatric effects that haven’t been added to the Rybelsus label.
Why Choose a Texas Rybelsus Attorney From Reich & Binstock
Selecting the right Texas Rybelsus lawyer can make a significant difference in the Rybelsus settlement you receive, especially if you’re filing a lawsuit against Novo Nordisk, a generic name drug manufacturer, pharmacy, or doctor for utilizing the prescription medication off-label. Our Rybelsus attorneys in Texas are investigating the risk factors and adverse event reports linked to Rybelsus and other GLP-1 drugs. Our Rybelsus lawsuit attorneys have established connections with experts in the medical community, have been lead or co-lead counsel in federal court and district courts in many cases, and are equipped to hold Novo Nordisk accountable on clients’ behalf.
We understand how disheartening it is to believe you have a cure for helping regulate blood sugar and later realized you weren’t able to make informed decisions because of the greed of the Rybelsus manufacturer, Novo Nordisk.
Our Texas Rybelsus attorneys have a deep understanding of federal law. We’re experienced at litigating in federal court, and offer free initial consultation to consumers across the U.S. who suffered optic nerve damage or vision loss, stomach paralysis, bowel obstruction, or other serious side effects of Rybelsus that Novo Nordisk didn’t properly warn about.
What is the Lawsuit Against Rybelsus?
Plaintiffs claim that the diabetes drug was marketed as a weight loss medication despite not being approved for weight loss. Other Rybelsus patients are filing a Rybelsus lawsuit alleging that they experienced serious side effects and health problems. Rybelsus and other semaglutide products underwent clinical trials, but plaintiffs claim that the drug company, Novo Nordisk, didn’t properly warn consumers about the health problems and health risks linked to use.
Plaintiffs allege the Rybelsus causes gastroparesis or stomach paralysis from impaired stomach muscles, vision loss from arteritic anterior ischemic optic neuropathy (NAION) or optic nerve damage, deep vein thrombosis (DVT) caused by blood clotting, and other side effects while taking Rybelsus.
Victims weren’t able to make informed decisions based on the actual and serious side effects. They have every right to explore legal options and demand fair Rybelsus settlements.
If you’ve been affected by Rybelsus side effects, contact a Texas Rybelsus attorney for a free, no-obligation consultation to discuss filing a Rybelsus lawsuit.
Allegations of Severe Gastrointestinal Injuries
The active ingredient in Rybelsus works by activating GLP-1 receptors in the body. This suppresses appetite, slows digestion, and creates lower blood sugar levels. While it helps regulate blood sugar as a diabetes treatment, it also causes more people to develop severe gastrointestinal issues compared to other drugs.
GI-related Rybelsus side effects that you can sue for include:
Stomach paralysis: This is the top risk factor in the Rybelsus MDL. Stomach paralysis occurs when your stomach muscles stop working. This slowing digestion causes food to sit in the digestive tract too long. Many who are filing a Rybelsus lawsuit argue the manufacturer should have disclosed this clearly.
Ileus and intestinal blockage: Another factor is that the Rybelsus MDL highlights the risk of developing ileus. This occurs when your intestines stop moving food and waste. This life-threatening event can block blood flow and waste, requiring hospitalization, surgical intervention, or feeding tubes.
Delayed gastric emptying problems: Slowed digestion is how semaglutide drugs like Rybelsus work, but this can progress to dangerous levels. When this nearly stops, it causes chronic vomiting, dehydration, and serious organ stress.
Gallbladder disease: Many cases also involve gallbladder issues, like gallstones and gallbladder inflammation, that require surgical removal. While listed on the warning label, plaintiffs argue that it didn’t highlight the severity of gallbladder disease or other side effects.
You may be able to file a lawsuit if you suffered stomach paralysis, bowel obstruction, or GI issues. Contact a Texas Rybelsus attorney for a free consultation to determine if you can pursue compensation through filing a Rybelsus lawsuit.
Ozempic, Wegovy, Rybelsus Weight Loss Drug Lawsuits for Gastroparesis and Stomach Injuries
In December 2024, the Food and Drug Administration (FDA) updated the warning label to cite a 2‑ to 7‑fold increased risk of gastrointestinal problems, including acute pancreatitis and gallbladder disease. This links the concerns raised about other GLP-1 drugs.
Rybelsis, Wegovy, and Ozempic lawsuit lawyers are all filing lawsuits based on the same significant impact after taking Rybelsus, or other drugs like Ozempic and Wegovy. Prescription drugs, like Rybelsus, work by slowing digestion. This has led to stomach paralysis, bowel obstruction, chronic vomiting, and chronic pain.
While only Wegovy got FDA approval as a weight loss drug, all three share the same active ingredient and came from the same company. The only difference is that Rybelsus works through an oral tablet while Ozempic and Wegovy are injections. Because they’re linked, multiple lawsuits are consolidated in federal court under the same product liability litigation.
If you need to file a Wegovy or Ozempic lawsuit, our Texas Ozempic lawsuit lawyers can help you take legal action.
Claims That Novo Nordisk Failed to Warn Patients About Severe Health Risks
Plaintiffs claim that Novo Nordisk didn’t adequately warn doctors or consumers about the life-threatening side effects of Rybelsus, including gastroparesis (stomach paralysis), persistent stomach pain, and chronic vomiting.
Other Rybelsus lawsuits involve other serious health issues, like deep vein thrombosis (DVT), blood clots, sudden vision loss, and other drug reactions.
Despite receiving FDA approval, several law firms, including our Texas Rybelsus attorneys, argue that the manufacturer knew and withheld critical information.
If you want to file a Rybelsus lawsuit in Texas, we can help you secure a fair Rybelsus settlement value or jury award for the impact the symptoms have on your life.
Off-Label Use As A Weight Loss Drug
Many Ozempic lawsuits and Rybelsus lawsuits filed allege that manufacturers Novo Nordisk and Eli Lilly indirectly encouraged using the diabetes treatment off-label to help lose weight. The Rybelsus manufacturer did so by emphasizing the effects as a weight loss medication even though the drug was only approved to treat Type 2 diabetes. In fact, despite class action lawsuits, the top of the Rybelsus website still says that it can “lower blood sugar levels and A1C, and may help you lose some weight.” Lower down, it states, ” While not for weight loss, it may help you lose some weight.”
Plaintiffs claim that the Rybelsus manufacturer highlighted clinical trials and testimonials demonstrating that slowing digestion helped them lose weight. This created the impression that the prescription drug was like other weight loss drugs. It insinuated that Rybelsus, Ozempic, and Wegovy had the same amount of active ingredients and that Rybelsus works the same way the other weight loss drugs do.
The Rybelsus manufacturer focused on body transformation and appetite suppression. This blurred the line between approved and unapproved use, causing physicians to rely on it as a popular weight loss drugs despite the absense of FDA approval for losing weight.
Rybelsus for Weight Loss: Who is Responsible for Severe Injuries?
More lawsuits are holding Novo Nordisk accountable. Novo Nordisk is responsible for manufacturing, getting FDA approval, and ensuring the warning label covers all health risks linked to Rybelsus. If the drug’s label didn’t properly warn about serious health complications like stomach paralysis, bowel obstruction, or other adverse reactions, responsibility falls on the company. This is why those filing Rybelsus lawsuits in the Rybelsus MDL are holding Novo Nordisk accountable directly.
Physicians can be held responsible if they:
- used Rybelsus off-label as a weight loss medication without telling you that it wasn’t approved as a weight loss drug,
- prescribed it to you when you already had issues with stomach muscles or stomach paralysis, or
- ignored new research about the higher risk factors when undergoing general anesthesia, and you aspirated under deep sedation because of the slow digestion.
Most cases are against Novo Nordisk for failing to warn doctors and consumers. If a medical provider acted outside of the accepted medical standards, both the manufacturer and prescriber share responsibility.
If you suffered serious health complications or the serious side effects of Rybelsus, contact a Texas Rybelsus attorney for a free consultation to discuss filing a Rybelsus lawsuit.
Who Qualifies to File a Rybelsus Lawsuit in Texas?
You may qualify to file an individual lawsuit instead of joining the class action lawsuit when the following applies. If you:
- suffered rare symptoms or unusually catastrophic complications that aren’t addressed in the Rybelsus MDL.
- have other serious health issues that aren’t related to vision loss, stomach paralysis, or bowel obstruction cases.
- have a Rybelsus claim that involves malpractice against a prescriber or a Texas Deceptive Trade Practices Act claim, instead of relying solely on the Rybelsus MDL.
- require a much higher Rybelsus settlement value due to higher out-of-pocket expenses that the global settlement won’t cover.
Most Rybelsus claims will be filed in the Rybelsus MDL, but in limited circumstances, an individual lawsuit is strategically better. If you need help determining whether filing a Rybelsus lawsuit individually or joining the class action is best, contact a Texas personal injury attorney for a free case evaluation.
Serious Complications or Conditions Caused by Rybelsus Use With Diagnosis
If you suffered health conditions or serious health complications linked to Rybelsus side effects or other weight loss drugs used without approval, you may be eligible to file a lawsuit:
- Gastroparesis (stomach paralysis)
- Ileus
- Bowel obstruction
- Health problems caused by slowing digestion
- Gallstones (cholelithiasis)
- Gallbladder disease, inflammation, or removal surgery (cholecystitis)
- Pancreatitis (inflammation of the pancreas)
- Kidney damage or kidney failure
- Worsening diabetic retinopathy or vision loss
- Aspiration tied to anesthesia
- Dehydration-related electrolyte imbalance, blood clots, or deep vein thrombosis (DVT)
However, you will need a medical diagnosis from a qualified physician to qualify to file a Rybelsus lawsuit in Texas.
Medical Records for Treatment, Surgery, or Hospitalization For Serious Medical Conditions or Adverse Reactions Caused by Rybelsus Use
If you’re taking Rybelsus and have experienced gastrointestinal problems, records outlining your medical condition are necessary for pursuing a semaglutide lawsuit. With all glucagon-like peptide 1 receptor agonists, Rybelsus side effects vary by individual circumstances.
If you’ve suffered harm and need to file a Rybelsus lawsuit in Texas, we’ll need your healthcare records and any recent studies or test results.
Statute of Limitations for Filing Rybelsus Claims
The legal deadline for filing a Rybelsus lawsuit in Texas is:
- Personal injury lawsuit: 2 years from the date of harm, when it was discovered, or should have been discovered.
- Wrongful death lawsuit: 2 years from the date of death. A Texas wrongful death lawyer can also assist with the legal process if a loved one was harmed by the weight loss drug.
The exceptions to the legal deadline for filing a Rybelsus lawsuit in Texas include:
- Minors: If a pediatric patient is hurt, they have until their 20th birthday to file a Rybelsus lawsuit in Texas.
- Mental incapacity: If the plaintiff is mentally incapacitated, the legal deadline may be paused until capacity is regained.
- Discovery rule: The clock starts when the health issue is discovered or reasonably should have been discovered. This is critical in Rybelsus lawsuits, since serious medical conditions like stomach paralysis or vision loss may not appear without prolonged use.
- Fraudulent concealment: Plaintiffs in the Rybelsus MDL continue to allege that Novo Nordisk concealed and misrepresented the potential health risks of stomach paralysis, bowel obstruction, and other health problems. So, Texas courts may allow the legal deadline to be tolled.
A Texas Rybelsus lawyer can help you apply the correct legal deadline to your case, especially for Rybelsus lawsuits linked to prolonged use.
If you’re experiencing serious side effects, our Texas Rybelsus attorneys need time to gather evidence and build a strong Rybelsus claim on your behalf.
Rybelsus Side Effects Named in Ongoing Rybelsus Litigation
Rybelsus side effects named in the ongoing Rybelsus class action lawsuit include
- Stomach paralysis
- Ileus
- Bowel obstruction
- Slowing digestion
- Persistent vomiting
- Serious stomach pain
- Dehydration and malnutrition
- Gallstones (cholelithiasis)
- Gallbladder disease, inflammation, or removal (cholecystitis)
- Pancreatitis
- Kidney injury or kidney failure
- Vision loss and vision problems like anterior ischemic optic neuropathy (AION), non-arteritic anterior ischemic optic neuropathy (NAION), arteric anterior optic neuropathy (AAION), optic nerve damage
- Aspiration and pulmonary aspiration under anesthesia
- Deep vein thrombosis (DVT)
Plaintiffs allege Novo Nordisk minimized the side effects of this high-risk medication. They argue that Novo Nordisk did not adequately warn patients or consumers of the long-term complications that emerged from prolonged or off-label use.
The Food and Drug Administration (FDA) and new research studies archived in the National Library of Medicine have documented the severity of gastrointestinal problems and vision problems linked to semaglutide medications.
Contact a Texas Rybelsus attorney for a free consultation to discuss your legal options for seeking compensation.
Rybelsus Thyroid Cancer
Thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), are explicitly disclosed on the FDA label of GLP-1 receptor agonists. So, the drug maker did technically disclose this. However, many plaintiffs argue that the warning only focuses on those with histories of MTC or MEN2. Others argue that Novo Nordisk aggressively marketed it as a safe weight loss drug, downplaying the boxed warning.
Some Rybelsus lawsuits involve claims that long-term cancer monitoring is inadequate and consumers weren’t fully informed about how little the manufacturer knew about human bodies compared to animal data.
So, you can file a Rybelsus lawsuit for thyroid cancer, but these cases are weaker than the stomach paralysis and bowel obstruction cases because the FDA warned about it.
Acute Pancreatitis, Chronic Pancreatitis, Necrotizing Pancreatitis, or Hemorrhagic Pancreatitis
The mechanism of slowing digestion and altering hormone activity increases pancreatic stress. Our Texas Rybelsus attorneys argue that Novo Nordisk didn’t disclose the heightened risk of developing life-threatening pancreatitis.
You may be eligible to file a Rybelsus lawsuit in Texas if you developed:
- Acute pancreatitis: sudden onset of serious stomach pain, often requiring emergency treatment.
- Chronic pancreatitis: repeated or ongoing pancreatic inflammation leading to digestive tract problems and chronic pain.
- Necrotizing pancreatitis: pancreatic tissue begins to die, creating a high risk of infection and systemic organ failure.
- Hemorrhagic pancreatitis: bleeding inside or around the pancreas, which can be fatal without immediate intervention.
If you were diagnosed with pancreatitis after taking Rybelsus, you may be entitled to pursue compensation. Contact a Texas Rybelsus lawyer for a free case review.
Rybelsus Pancreatic Cancer
The Rybelsus label does warn about acute pancreatitis, and those taking Rybelsus are advised to stop if pancreatitis develops. Established research confirms that chronic pancreatitis is a known risk factor for pancreatic cancer. However, the Food and Drug Administration (FDA) insists that no new research provides a “proven link” between GLP-1 drugs and an increase in pancreatic cancer, despite decades of the FDA’s history of relying heavily on pharmaceutical company submissions.
The Rybelsus class action lawsuit lists pancreatitis at its core, while pancreatic cancer is included in some filings. Essentially, the FDA is downplaying that this is a high-risk medication for pancreatic cancer while openly admitting the prescription drug causes pancreatitis.
Our Texas Rybelsus lawsuit lawyers can help you cut through the Food and Drug Administration’s negligence by exposing how regulators accepted the company’s data while failing to ensure consumer safety. When filing Rybelsus lawsuits in Texas, we’ll use medical records, diagnosis, and treatment history to highlight the contradictions and the agency’s dismissal of pancreatic cancer concerns and hold the manufacturer responsible despite the FDA’s inaction.
Gastroparesis (Stomach Paralysis) and Delayed Gastric Emptying
Many Rybelsus lawsuits allege that Rybelsus causes gastroparesis (stomach paralysis). It occurs when the stomach muscles fail to move food properly to the small intestine. Stomach paralysis is linked to the GLP-1 drugs for slowing digestion.
If you want to file a Rybelsus lawsuit in Texas or join the class action, contact a lawyer for a free consultation.
Intestinal Obstruction, Ileus, and Intestinal Blockage
Intestinal obstruction, ileus, bowel obstruction, and intestinal blockage are central allegations in the ongoing Rybelsus lawsuits. These serious medical conditions occur when the digestive tract is blocked. These health conditions have resulted in emergency room visits, hospitalizations, and surgeries.
If you’ve suffered one of these medical conditions, contact a Texas Rybelsus lawsuit lawyer for a free, no-obligation consultation.
Gallbladder Disease or Gallstones Requiring Surgery
Some people taking Rybelsus have alleged suffering from gallbladder disease and gallbladder issues, gallstones, that result in cholecystitis and gallbladder removal surgery. Plaintiffs claim that the manufacturer minimized the severity while the number of emergency room visits and surgical interventions increased from Rybelsus use.
Call a Texas Rybelsus lawsuit lawyer for a free consultation to discuss filing a Rybelsus lawsuit.
Acute Kidney Injury (Linked to Chronic Vomiting and Dehydration)
Acute kidney injury is a medical condition identified in the Rybelsus class action lawsuit when persistent vomiting and severe dehydration lead to kidney damage or failure. Our Texas Rybelsus lawsuit lawyers can use hospital records, lab results, and adverse event reports to link GLP-1 use directly to kidney damage. By building this evidence, we help victims secure financial compensation and increase potential settlement values.
Diabetic Retinopathy, Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), and Sudden Vision Loss
Non-arteritic anterior ischemic optic neuropathy (NAION) has been linked to GLP-1 use. A matched cohort study published in JAMA Ophthalmology found that semaglutide users had a statistically significant increase in NAION occurrence compared to non-GLP-1 RA users. NAION occurs when blood vessels supplying the optic nerve block blood flow, leading to sudden vision loss. This serious eye condition is now cited in litigation, and victims may pursue compensation for the following with the help of a Texas Rybelsus lawsuit lawyer: NAION, AAION, AION, diabetic retinopathy, optic nerve ischemia, and sudden vision loss.
Pulmonary Embolism, Blood Clot, and Deep Vein Thrombosis (DVT)
Pulmonary embolism, blood clots, and deep vein thrombosis (DVT) are life-threatening health conditions cited in the Rybelsus litigation. The PIONEER and SUSTAIN trials found that GLP-1 users had a 266% increased risk of developing DVT. Deep vein thrombosis (DVT) develops when a blood clot forms in a deep vein that travels to the lungs, causing a pulmonary embolism that blocks blood flow and may be fatal.
If you’ve suffered a pulmonary embolism, DVT, or clot, consult a Texas Rybelsus lawsuit lawyer through a free consultation.
Bowel Obstruction Requiring Hospitalization
Bowel obstruction has become a key issue in the Rybelsus lawsuits because the Food and Drug Administration did not put it on the official label, even though it listed minor digestive side effects like nausea, vomiting, and constipation. Patients have been hospitalized and required surgery for complete blockages after GLP-1 use. A 2025 case report confirmed real-world evidence that bowel obstruction occurs. A Texas Rybelsus lawsuit lawyer can help plaintiffs argue that Novo Nordisk failed to disclose this life-threatening medical condition and work to secure financial compensation.
Abnormal Liver Function / Elevated Liver Enzymes
Abnormal liver function and elevated liver enzymes have been reported in patients taking semaglutide, though these issues are not listed on the FDA label. A pharmacovigilance study detected links of drug-induced liver damage connected to GLP-1 receptor agonists. Our Texas Rybelsus lawsuit lawyers can help by gathering liver function test results, linking the harm to GLP-1 use, and seeking financial compensation on your behalf.
Hypoglycemia (Dangerously Lower Blood Sugar Levels)
The manufacturer failed to properly warn about the dangers of hypoglycemia in patients taking Rybelsus. The drug’s active ingredient, semaglutide, increases insulin production and insulin release while it reduces glucagon secretion, making it harder for the body to regulate blood sugar. When combined with other semaglutide medications or certain diabetes treatments, this effect can lower blood sugar levels to dangerous amounts. Severe hypoglycemia can block blood flow and damage blood vessels, creating life-threatening emergencies. The drug manufacturer encouraged use among weight loss patients, but patients who were prescribed Rybelsus as a weight loss drug suffered serious side effects. If you have serious health issues, call a Texas Rybelsus lawsuit lawyer for a free consultation.
Gastrointestinal Bleeding and Rectal Bleeding
Gastrointestinal bleeding and rectal bleeding are not listed on the official FDA label, but post-marketing reports have identified these events in patients using GLP-1 drugs. A Canadian review noted reported cases of rectal bleeding and adverse event reports in FAERS, and has also found over 5,000 documented reports of serious health issues like gastrointestinal hemorrhage. If you need assistance filing a Rybelsus lawsuit in Texas, call our experienced lawyers for a free consultation.
Persistent Acid Reflux of GERD
Some patients taking Rybelsus have reported persistent acid reflux or gastroesophageal reflux disease (GERD). Although not included on the FDA label, a FAERS disproportionality analysis found reports of GERD associated with GLP-1 drugs. Plaintiffs claim that prolonged reflux can signal more severe GI issues than were disclosed.
Emerging Rybelsus Claims Our Legal Team is Reviewing
Our Texas Rybelsus lawsuit attorney team is reviewing cases for product liability litigation involving patients taking Rybelsus or other semaglutide drugs. Patient and expert reports include GI disorders, gallbladder disease, blood clots, vision loss, and other serious complications requiring emergency treatment or surgery.
If your diagnosis and medical expenses are linked to GLP-1 use, you may qualify to file a personal injury lawsuit. Our experienced lawyers can collect your medical records, consult experts, and use evidence to prove that the prescription drug caused severe injuries. We seek compensation for medical bills, future treatment costs, lost wages, and pain and suffering.
If you suffered harm and want to take legal action, our Texas products liability litigation attorneys provide a free case review to discuss filing a Rybelsus lawsuit.
Other Rybelsus Cancer Risks: Bile Duct Cancer, Kidney Cancer, and Colorectal Cancer
Plaintiffs claim they developed cancer after taking Rybelsus. A BMJ cohort study linked GLP-1 use to bile duct cancer. Additionally, a JAMA Oncology analysis found a link to GLP-1 and kidney cancer. For colorectal cancer, a PubMed study suggested a possible increased risk. Despite so much conflicting data, plaintiffs’ lawyers argue that the manufacturer was extremely negligent in investigating higher risks for cancer.
Pulmonary Aspiration
Pulmonary aspiration is a complication linked to GLP-1 use because delayed gastric emptying leaves food during procedures requiring general anesthesia or sedation. If contents enter the lungs, patients develop aspiration pneumonia or respiratory failure. The American Society of Anesthesiologists issued guidance warning that GLP-1 receptor agonists pose a heightened risk of aspiration.
A Texas Rybelsus lawsuit lawyer can help you seek maximum compensation.
ALS (Lou Gehrig’s disease)
A recent study by the Neurology Journal found that patients with ALS who had diabetes and were treated with GLP-1, including semaglutide, experienced shorter survival times. So, this recent study raises significant concern about worsening outcomes in patients who develop the disease. The manufacturer didn’t investigate or warn whatsoever about contributing to neurological decline.
Rybelsus Lawsuit Update 2025: GLP-1 Multidistrict Litigation (MDL 3094)
2019: FDA approval of Rybelsus, the first glucagon-like peptide 1 receptor agonist as a type 2 diabetes treatment. The warning label included thyroid C-cell tumors, plus potential health risks of pancreatitis, kidney damage, gallbladder disease, and diabetic retinopathy-related health issues.
2021–2022: Early stages of GLP-1 drugs used to help lose weight despite having FDA approval as a diabetes treatment. Growing number of consumers alleging gastroparesis (stomach paralysis), bowel obstruction, and chronic pain, and other serious health issues. FDA strengthened warnings on the Rybelsus label about sudden vision loss and other vision problems.
2023: Allegations against manufacturer Novo Nordisk for developing severe gastrointestinal issues and other side effects that required emergency room visits. The American Medical Association and National Institutes of Health flagged the high demand and increased risk of developing severe gastrointestinal issues from of off label use. The American Society of Anesthesiologists issued warnings that GLP-1 drugs like Rybelsus pose increased risk during general anesthesia and deep sedation because of slowing digestion, leading to pulmonary aspiration hazards. The FDA and EMA launched formal safety reviews into GLP-1 drugs for stomach paralysis, ileus, psychiatric effects, and other serious health issues from the prescription and other semaglutide medications.
February 2024: Motions filed to consolidate many cases into multidistrict litigation. Plaintiffs alleged Novo Nordisk failed to adequately warn consumers, failed to warn doctors, and downplayed serious health problems linked to the prescription drug and other semaglutide medications.
April 2024: The Judicial Panel on Multidistrict Litigation created MDL No. 3094: In Re: GLP-1 Receptor Agonists Products Liability Litigation in the Eastern District of Pennsylvania. This is assigned to the Honorable Gene E.K. Pratter. First status conference held in June. The plaintiffs’ executive committee was appointed to oversee leadership and coordinate discovery for legal deadlines, marketing discovery, and out-of-pocket expenses.
Mid to Late 2024: The legal process enters discovery. Courts continued receiving a rising volume of filings involving gastroparesis, ileus, gallbladder disease, and vision complications. Defense and plaintiffs’ lawyers exchange documents. Pretrial orders in MDL 3094 established for all GLP 1 cases. Expert retention scheduling began. Core medical records became mandatory for all plaintiffs. Warning label updates for semaglutide drugs as high-risk medication for pancreatitis and gallbladder disease.
Early 2025: Status conferences focused on coordinating findings for all GLP-1 drugs. Criteria for the first wave of bellwether eligibility advanced. Discovery continued across thousands of filings involving semaglutide medications. As of December 2025, the MDL recorded 2,914 total GLP-1 cases pending.
If you received a diagnosis for a health condition or suffered serious health issues from a diabetes or weight loss prescription medication, a Texas Rybelsus lawyer can help you pursue compensation.
Rybelsus Included in Federal Multidistrict Litigation in Eastern District of Pennsylvania
Rybelsus and other semaglutide medications, like Ozempic and Wegovy, are part of a consolidated federal multidistrict litigation in the Eastern District of Pennsylvania. This brings together hundreds of Rybelsus lawsuits alleging that patients suffered severe gastrointestinal injuries and other complications after using the drug.
Although Rybelsus is FDA-approved for the treatment of type 2 diabetes, our Texas Rybelsus lawsuit lawyers argue that the manufacturer failed to provide adequate warnings about gastroparesis and other conditions. The court allows plaintiffs’ lawyers to streamline evidence gathering, expert testimony, and pretrial proceedings for more efficient case management.
Judge Karen S. Marston Now Overseeing Judicial Panel on Multidistrict Litigation
The Judicial Panel on Multidistrict Litigation (JPML) centralized semaglutide lawsuits, including Rybelsus, Ozempic, Wegovy, Trulicity, and Mounjaro, into MDL No. 3094 in the Eastern District of Pennsylvania, assigning oversight to U.S. District Judge Pratter. Tragically, Judge Pratter passed away unexpectedly. The JPML reassigned the Rybelsus MDL to District Judge Karen S. Marston, who quickly held status conferences, issued case-management orders to move the litigation forward
Status of Evidentiary Hearings, Expert Reports, and Scientific Evidence
As of August 2025, MDL No. 3094 involving Rybelsus is centered on expert reports and scientific evidence, with both sides exchanging opinions on whether GLP-1 products can cause stomach paralysis and other serious medical conditions. Judge Karen Marston has already held evidentiary hearings, and the federal court is now weighing challenges under Rule 702. This will decide which scientific evidence and testimony jurors hear.
Diabetes Treatments Named: Mounjaro, Rybelsus, Ozempic, and Wegovy
The litigation targets GLP-1 diabetes treatments, including Mounjaro, Rybelsus, Ozempic, and Wegovy. Plaintiffs allege undisclosed drug risks, like delayed gastric emptying and long-term digestive tract damage. Rybelsus claims focus on the lack of adequate warnings that left patients and physicians unaware of the severity of side effects. Rybelsus, Wegovy, and Ozempic lawsuit lawyers seek to hold pharmaceutical companies accountable while seeking compensation for medical expenses, lost wages, and lasting health problems.
Potential Rybelsus Lawsuit Settlement Value and Payout Process
In the Texas Rybelsus lawsuit, plaintiffs involve claims for a wide range of damages, including medical expenses, lost wages, and emotional distress caused by severe side effects. If the court finds that the manufacturer failed to provide adequate warnings on the drug’s label, patients may be entitled to possible compensation through verdicts or a global settlement. Global settlement values will vary based on the individual case.
When global settlements are reached, the court approves the payout process and distributes the individual global settlement value to qualifying patients through structured or lump-sum payments.
Other GLP-1 Lawsuits Our Texas Law Firm Handles
In addition to filing a Rybelsus lawsuit, our Texas drug injury lawyers help patients with other GLP-1 medication cases. Most claims focus on inadequate warning labels for stomach paralysis, gallbladder disease, bowel obstruction, vision loss, and other serious health complications. Like Rybelsus litigation, these cases aim to hold drug manufacturers accountable for failing to adequately inform patients and healthcare providers of the serious side effects and symptoms of their medications.
By representing clients across multiple GLP-1 drug cases, our firm leverages scientific evidence, expert testimony, and legal strategy to pursue maximum compensation. We have the following Texas GLP-1 lawsuit attorneys on staff:
Ozempic lawsuit lawyers
Texas Zepbound lawyer
Contact a Texas Rybelsus Lawyer For a Free Consultation
If you or a loved one experienced serious side effects after taking Rybelsus, you may be eligible to file a Rybelsus lawsuit to seek compensation for your injuries, medical expenses, and other losses. Our legal team offers a free, no-obligation case review to determine whether filing lawsuits against the manufacturer is your best legal option.
For a free consultation with a Texas Rybelsus lawyer, call 713-622-7271 or complete our online consultation form.
There is never a fee unless we recover on your behalf.
Additionally, clients are not obligated to pay expenses if a recovery is not made.
